RBC Capital analyst Gregory Renza maintained a Buy rating on Spruce Biosciences (SPRB) on May 12 and set a price target of $27.00.
The post Spruce Biosciences (SPRB) Gets a Buy Rating from RBC Capital appeared first on Smarter Analyst.
RBC Capital analyst Gregory Renza maintained a Buy rating on ...

https://www.smarteranalyst.com/new-blurbs/spruce-biosciences-sprb-gets-a-buy-rating-from-rbc-capital/

#SmarterAnalyst